Skip to main content
Delfa

← Trials/Trial dossier/NCT04737096

CompletedPhase 2

DAOIB Combined With tDCS for Early-phase Dementia

DAOIB Combined With tDCS for Early-phase Dementia - a Randomized, Double-blinded and Placebo Controlled Clinical Trial

Asset

DAOIB

Listed sites

1

Recruiting sites

-

Enrollment

97

actual

Study population

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Key I/E criteria

•Alzheimer's disease•MMSE 10-26

Primary endpoint

•The Alzheimer's disease assessment scale - cognitive subscale

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID201601789A0C603
NCT IDNCT04737096

Timeline

Milestones

Study start2020-01-01actual
Study first posted2021-02-03actual
Primary completion2023-01-02actual
Study completion2023-01-02actual
Last update posted2023-01-06actual

Assets

Drug assets

DAOIB

Study populations

Who this study enrolls

Alzheimer’s diseaseMCI / preclinical Alzheimer’s

Eligibility

Who can enroll

Minimum age50 Years
Maximum age100 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
•MMSE between 10-26
•CDR 1 or 0.5

Exclusion criteria

•Hachinski Ischemic Score > 4
•Substance abuse/dependence
•Parkinson disease, epilepsy, dementia with psychotic features
•Major depressive disorder
•Major physical illnesses
•Severe visual or hearing impairment

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Caregiver / quality of life
2
Global cognition
1
Memory
1
Function / daily living
1
Other (unclassified)
1

Global cognition

1 endpoint
Secondary/protocol endpoint

Change from baseline in Mini-Mental Status examination score at week 8, 16 and 24

Time frame:week 0, 8, 16, 24

Mini-Mental State Examination (MMSE)

change from baseline, improvement

Memory

1 endpoint
Secondary/protocol endpoint

Change from baseline in the composite score of a battery of additional cognitive tests at week 24

Time frame:week 0, 24

change from baseline, improvement

Function / daily living

1 endpoint
Secondary/protocol endpoint

Change from baseline in Alzheimer's disease Cooperative Study scale for ADL in MCI (ADCS-MCI-ADL) score at week 8, 16 and 24

Time frame:week 0, 8, 16, 24

change from baseline, improvement

Caregiver / quality of life

2 endpoints
Secondary/protocol endpoint

Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24

Time frame:week 8, 16, 24

change from baseline, improvement

Secondary/protocol endpoint

Change from baseline in Quality of life score at week 8, 16 and 24

Time frame:week 0, 8, 16, 24

change from baseline, improvement

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24

Time frame:week 0, 8, 16, 24

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.